{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:10:03Z","timestamp":1794370203827,"version":"4.9.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study Objectives<\/jats:title>\n                    <jats:p>Idiopathic\/isolated Rapid Eye Movement (REM) sleep behavior disorder (iRBD) is recognized as a prodromal stage of neurodegenerative diseases, particularly of \u03b1-synucleinopathies. The development of blood-based biomarkers enables the in vivo assessment of neuronal, glial, and Alzheimer\u2019s disease (AD)-related changes. This study aimed to analyze plasma levels of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated-Tau 181 (pTau181) in iRBD patients compared to healthy controls (HC) and AD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study, iRBD patients were compared to age- and sex-matched HC and AD patients. All participants underwent cognitive and motor assessments. Plasma NfL, GFAP, and pTau181 levels were quantified using SIMOA (Quanterix, Billerica, MA). Analyses of covariance and Spearman correlation coefficients were used for group comparisons and correlation analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 44 iRBD patients (81.8% males, mean age 71.0\u2009\u00b1\u20096.4\u00a0years), 55 HC (66.3% males, mean age 69.1\u2009\u00b1\u20095.5\u00a0years), and 28\u00a0AD patients (82.1% males, mean age of 70.4\u2009\u00b1\u20096.7\u00a0years). iRBD patients showed significantly higher plasma NfL and GFAP levels and similar pTau181 levels compared to HC. Compared to AD patients, iRBD patients had lower levels of GFAP, NfL, and pTau181. In iRBD, GFAP and NfL levels were significantly correlated, while no correlations were observed between plasma biomarkers and clinical symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High plasma NfL and GFAP levels in iRBD patients reflect a possible ongoing neurodegenerative process. Normal pTau181 plasma levels in iRBD suggest that AD-related neurodegeneration is not present at this stage. Future studies on plasma markers predicting phenoconversion are crucial for setting neuroprotective interventions in iRBD patients.<\/jats:p>\n                    <jats:p>Statement of Significance This study identifies plasma biomarkers that reflect neurodegeneration in idiopathic\/isolated REM sleep behavior disorder (iRBD), a prodromal stage of \u03b1-synucleinopathies. Higher plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels in iRBD patients compared to healthy controls suggest early neuronal and glial degeneration, while similar phosphorylated-Tau 181 levels indicate an absence of Alzheimer\u2019s disease co-pathology. These findings support the utility of NfL and GFAP as potential blood-based markers for tracking early neurodegenerative changes in iRBD. Further studies focusing on these markers in predicting disease progression could be instrumental in guiding timely neuroprotective interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/sleep\/zsaf163","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:51:48Z","timestamp":1749196308000},"source":"Crossref","is-referenced-by-count":9,"title":["Plasma NfL, GFAP, and pTau181 in patients with isolated REM sleep behavior disorder"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-1332","authenticated-orcid":false,"given":"Claudio","family":"Liguori","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]},{"name":"Sleep Medicine Center, Neurology Unit, University Hospital of Rome Tor Vergata , Viale Oxford 81, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Zatti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Carpi","sequence":"additional","affiliation":[{"name":"Sleep Medicine Center, Neurology Unit, University Hospital of Rome Tor Vergata , Viale Oxford 81, 00133, Rome ,","place":["Italy"]},{"name":"Department of Human Neurosciences, Sapienza University of Rome , Piazzale Aldo Moro 5, 00185, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tolassi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Department of Continuity of Care and Frailty, Neurology Unit, ASST Spedali Civili Hospital , Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]},{"name":"Department of Molecular and Translational Medicine, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili Hospital , Viale Europa 11 and Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Testone","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Antonucci","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Bergamo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Risino","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Benedetti","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e8e","family":"Caon","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Quaresima","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Department of Continuity of Care and Frailty, Neurology Unit, ASST Spedali Civili Hospital , Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]},{"name":"Department of Molecular and Translational Medicine, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili Hospital , Viale Europa 11 and Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Galli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rizzardi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Girotto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Department of Continuity of Care and Frailty, Neurology Unit, ASST Spedali Civili Hospital , Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]},{"name":"Department of Molecular and Translational Medicine, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili Hospital , Viale Europa 11 and Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Trasciatti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Department of Molecular and Translational Medicine, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lupini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Eshja","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Giliani","sequence":"additional","affiliation":[{"name":"Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili Hospital , Viale Europa 11 and Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Department of Continuity of Care and Frailty, Neurology Unit, ASST Spedali Civili Hospital , Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]},{"name":"Department of Molecular and Translational Medicine, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili Hospital , Viale Europa 11 and Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]},{"name":"Brain Health Center, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Via Montpellier 1, 00133, Rome ,","place":["Italy"]},{"name":"Sleep Medicine Center, Neurology Unit, University Hospital of Rome Tor Vergata , Viale Oxford 81, 00133, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pilotto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Viale Europa 11, 25123, Brescia","place":["Italy"]},{"name":"Department of Continuity of Care and Frailty, Neurology Unit, ASST Spedali Civili Hospital , Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]},{"name":"Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili Hospital , Viale Europa 11 and Piazzale Spedali Civili 1, 25123, Brescia ,","place":["Italy"]},{"name":"Center for Alzheimer Research, Division of Clinical Geriatrics Department of Neurobiology, Care Sciences and Society (NVS) Karolinska Institutet , SE-141 83, Huddinge, Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"issue":"6","key":"2025121103124265200_ref1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"2025121103124265200_ref2","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2025121103124265200_ref3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"Lancet Neurol"},{"issue":"s2","key":"2025121103124265200_ref4","doi-asserted-by":"publisher","first-page":"S333","DOI":"10.3233\/JPD-240007","article-title":"Biofluid markers and tissue biopsies analyses for the prodromal and earliest phase of Parkinson\u2019s disease","volume":"14","author":"Pilotto","year":"2024","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"2025121103124265200_ref5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/mds.28026","article-title":"Intraindividual neurofilament dynamics in serum mark the conversion to sporadic Parkinson\u2019s disease","volume":"35","author":"Wilke","year":"2020","journal-title":"Mov Disord"},{"issue":"7","key":"2025121103124265200_ref6","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1212\/WNL.0000000000010084","article-title":"NfL as a biomarker for neurodegeneration and survival in Parkinson disease","volume":"95","author":"B\u00e4ckstr\u00f6m","year":"2020","journal-title":"Neurology."},{"key":"2025121103124265200_ref14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","article-title":"The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies","volume":"43","author":"Galbiati","year":"2019","journal-title":"Sleep Med Rev"},{"key":"2025121103124265200_ref15","doi-asserted-by":"publisher","first-page":"e89741","DOI":"10.1371\/journal.pone.0089741","volume-title":"PLoS One","author":"Iranzo","year":"2014"},{"issue":"8","key":"2025121103124265200_ref16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1474-4422(21)00176-9","article-title":"Biomarkers of conversion to \u03b1-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder","volume":"20","author":"Miglis","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"2025121103124265200_ref7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"\u0391-synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid\u2014a systematic review and meta-analysis","volume":"10","author":"Grossauer","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"2025121103124265200_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107256","article-title":"The \u03b1-synuclein seed amplification assay: interpreting a test of Parkinson\u2019s pathology","volume":"131","author":"Espay","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2025121103124265200_ref9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2013.10","article-title":"Cerebrospinal fluid biomarkers in Parkinson disease","volume":"9","author":"Parnetti","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"2025121103124265200_ref10","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1111\/ejn.16290","article-title":"How close are we to a breakthrough? The hunt for blood biomarkers in Parkinson\u2019s disease diagnosis","volume":"59","author":"Liu","year":"2024","journal-title":"Eur J Neurosci"},{"issue":"1","key":"2025121103124265200_ref11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/alz.12814","article-title":"Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design","volume":"19","author":"Toledo","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2025121103124265200_ref12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/biom14040398","article-title":"Biomarkers for managing neurodegenerative diseases","volume":"14","author":"Cheslow","year":"2024","journal-title":"Biomolecules"},{"issue":"7","key":"2025121103124265200_ref13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1136\/jnnp-2022-330048","article-title":"Prognostic biomarkers in prodromal \u03b1-synucleinopathies: DAT binding and REM sleep without atonia","volume":"94","author":"Kunz","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"2025121103124265200_ref17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3233\/JAD-210342","article-title":"Plasma neurofilament light chain predicts cognitive progression in prodromal and clinical dementia with Lewy bodies","volume":"82","author":"Pilotto","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"2025121103124265200_ref18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.parkreldis.2021.04.016","article-title":"Plasma NfL, clinical subtypes and motor progression in Parkinson\u2019s disease","volume":"87","author":"Pilotto","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2025121103124265200_ref19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-020-00385-5","article-title":"Utility of plasma neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease","volume":"15","author":"Ng","year":"2020","journal-title":"Mol Neurodegener"},{"key":"2025121103124265200_ref20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.parkreldis.2022.05.020","article-title":"Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson\u2019s disease","volume":"105","author":"Pagonabarraga","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"2025121103124265200_ref21","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1007\/s00415-023-11785-0","article-title":"Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder","volume":"270","author":"Park","year":"2023","journal-title":"J Neurol"},{"issue":"4","key":"2025121103124265200_ref22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3233\/JPD-223519","article-title":"Neurofilament light protein predicts disease progression in idiopathic REM sleep behavior disorder","volume":"13","author":"Zhang","year":"2023","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"2025121103124265200_ref23","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/alz.13653","article-title":"Plasma biomarkers of Alzheimer\u2019s disease in the continuum of dementia with Lewy bodies","volume":"20","author":"Diaz-Galvan","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2025121103124265200_ref24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"2025121103124265200_ref27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/mds.28370","article-title":"Plasma Phospho-tau identifies Alzheimer\u2019s Co-pathology in patients with Lewy body disease","volume":"36","author":"Hall","year":"2021","journal-title":"Mov Disord"},{"issue":"12","key":"2025121103124265200_ref25","doi-asserted-by":"publisher","first-page":"209418","DOI":"10.1212\/WNL.0000000000209418","article-title":"Association of Plasma Amyloid, P-tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with Lewy bodies","volume":"102","author":"Bolsewig","year":"2024","journal-title":"Neurology."},{"issue":"3","key":"2025121103124265200_ref26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ana.27003","article-title":"Plasma pTau181 reveals a pathological signature that predicts cognitive outcomes in Lewy body disease","volume":"96","author":"Abdelnour","year":"2024","journal-title":"Ann Neurol"},{"key":"2025121103124265200_ref28","volume-title":"International Classification of Sleep Disorders","author":"American Academy of Sleep Medicine"},{"key":"2025121103124265200_ref29","first-page":"153","article-title":"Unified Parkinson\u2019s disease rating scale","volume":"2","author":"Fahn","journal-title":"Recent Dev Park Dis"},{"issue":"6","key":"2025121103124265200_ref30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep."},{"issue":"6","key":"2025121103124265200_ref31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s100720300004","article-title":"Italian version of the Epworth sleepiness scale: external validity","volume":"23","author":"Vignatelli","year":"2003","journal-title":"Neurol Sci"},{"issue":"6","key":"2025121103124265200_ref32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"2025121103124265200_ref33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.parkreldis.2016.10.020","article-title":"Validation of the Italian version of the non motor symptoms scale for Parkinson\u2019s disease","volume":"34","author":"Cova","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"issue":"19","key":"2025121103124265200_ref34","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/WNL.0b013e3181c0d416","article-title":"International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease","volume":"73","author":"Martinez-Martin","year":"2009","journal-title":"Neurology."},{"issue":"4","key":"2025121103124265200_ref35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2025121103124265200_ref36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/ADR-210053","article-title":"MoCA 7.1: multicenter validation of the first Italian version of Montreal cognitive assessment","volume":"6","author":"Pirani","year":"2022","journal-title":"J Alzheimer\u2019s Dis Reports"},{"key":"2025121103124265200_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2024.08.007","article-title":"Plasma P-Tau181 and amyloid markers in Alzheimer\u2019s disease: a method comparison between Simoa and Lumipulse","volume":"143","author":"Quaresima","year":"2024","journal-title":"Neurobiol Aging"},{"issue":"2","key":"2025121103124265200_ref38","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/awae368","article-title":"Plasma p-tau217 in Alzheimer\u2019s disease: Lumipulse and ALZpath SIMOA head-to-head comparison","volume":"148","author":"Pilotto","year":"2025","journal-title":"Brain."},{"key":"2025121103124265200_ref39","first-page":"27","volume-title":"Leading-Edge Psychological Tests and Testing Research","author":"Sica","year":"2007"},{"issue":"3","key":"2025121103124265200_ref40","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3233\/JAD-215646","article-title":"Differences between plasma and cerebrospinal fluid p-tau181 and p-tau231 in early Alzheimer\u2019s disease","volume":"87","author":"Pilotto","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"2025121103124265200_ref41","volume-title":"Multivariate Data Analysis","author":"Hair","year":"2010","edition":"7th"},{"key":"2025121103124265200_ref46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.12703\/r\/10-46","article-title":"Neurofilament light: a narrative review on biomarker utility","volume":"10","author":"Narayanan","year":"2021","journal-title":"Fac Rev"},{"issue":"1","key":"2025121103124265200_ref47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0006-8993(03)03219-0","article-title":"Elevated neurofilament levels in neurological diseases","volume":"987","author":"Norgren","year":"2003","journal-title":"Brain Res"},{"issue":"9","key":"2025121103124265200_ref48","doi-asserted-by":"publisher","first-page":"e16371","DOI":"10.1111\/ene.16371","article-title":"Cerebrospinal fluid and blood neurofilament light chain levels in amyotrophic lateral sclerosis and frontotemporal degeneration: a meta-analysis","volume":"31","author":"Verde","year":"2024","journal-title":"Eur J Neurol"},{"issue":"4","key":"2025121103124265200_ref49","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3233\/JAD-231080","article-title":"The predictive ability of blood neurofilament light chain in predicting cognitive decline in the Alzheimer\u2019s disease continuum: a systematic review and meta-analysis","volume":"97","author":"Li","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"2025121103124265200_ref50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.parkreldis.2022.06.004","article-title":"Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: a systematic review and meta-analysis","volume":"101","author":"Wong","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"2025121103124265200_ref51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neulet.2018.07.030","article-title":"Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: a meta-analysis","volume":"685","author":"Ge","year":"2018","journal-title":"Neurosci Lett"},{"issue":"1","key":"2025121103124265200_ref52","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"2025121103124265200_ref53","doi-asserted-by":"publisher","first-page":"209537","DOI":"10.1212\/WNL.0000000000209537","article-title":"Blood astrocyte biomarkers in Alzheimer disease","volume":"103","author":"Holper","year":"2024","journal-title":"Neurology."},{"issue":"9","key":"2025121103124265200_ref54","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/cells12091309","article-title":"GFAP as a potential biomarker for Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"12","author":"Kim","year":"2023","journal-title":"Cells."},{"issue":"1","key":"2025121103124265200_ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00745-8","article-title":"Plasma biomarkers of neurodegeneration in patients and high risk subjects with Lewy body disease","volume":"10","author":"Hiraga","year":"2024","journal-title":"NPJ Park Dis"},{"issue":"1","key":"2025121103124265200_ref56","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13195-024-01502-y","article-title":"Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies","volume":"16","author":"Vrillon","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"2025121103124265200_ref57","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/acn3.51768","article-title":"Plasma GFAP associates with secondary Alzheimer\u2019s pathology in Lewy body disease","volume":"10","author":"Cousins","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"2025121103124265200_ref58","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","article-title":"Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy","volume":"93","author":"Chouliaras","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2025121103124265200_ref59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-023-00447-7","article-title":"Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia","volume":"9","author":"Tang","year":"2023","journal-title":"NPJ Park Dis"},{"issue":"12","key":"2025121103124265200_ref60","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"2025121103124265200_ref61","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsx041","article-title":"Excessive daytime sleepiness predicts neurodegeneration in idiopathic REM sleep behavior disorder","volume":"40","author":"Zhou","year":"2017","journal-title":"Sleep."},{"issue":"1","key":"2025121103124265200_ref64","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41398-021-01423-6","article-title":"Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression","volume":"11","author":"Michel","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2025121103124265200_ref62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2014.01.012","article-title":"Altered expression of glial and synaptic markers in the anterior hippocampus of behaviorally depressed female monkeys","volume":"563","author":"Willard","year":"2014","journal-title":"Neurosci Lett"},{"key":"2025121103124265200_ref63","doi-asserted-by":"publisher","first-page":"746491","DOI":"10.3389\/fphar.2021.746491","article-title":"Sex differences in behavioral symptoms and the levels of circulating GFAP, tau, and NfL in patients with traumatic brain injury","volume":"12","author":"Sass","year":"2021","journal-title":"Front Pharmacol"},{"issue":"8","key":"2025121103124265200_ref65","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/mds.27090","article-title":"A user\u2019s guide for \u03b1-synuclein biomarker studies in biological fluids: perianalytical considerations","volume":"32","author":"Mollenhauer","year":"2017","journal-title":"Mov Disord"}],"container-title":["SLEEP"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsaf163\/63455858\/zsaf163.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/48\/12\/zsaf163\/63455858\/zsaf163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/48\/12\/zsaf163\/63455858\/zsaf163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:12:51Z","timestamp":1765440771000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsaf163\/8158655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":61,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6,9]]},"published-print":{"date-parts":[[2025,12,11]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsaf163","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,6,9]]},"article-number":"zsaf163"}}